Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_4466_Библиотеки_им_академика_М_И_Перельмана
.pdf
464
https://t.me/medicina_free
T. A. Teke et al.
space. Corticosteroids have known potent activities in limiting inammation.
Corticosteroids were used to manage bacterial meningitis to minimize the subarachnoid space inammation and decrease several manifestations such as vasogenic
brain edema, increased intracranial pressure, cerebral blood ow changes, cerebral
vasculitis, and neuronal injury [23–25]. The effect of corticosteroids on mortality
rate, HL, and other neurologic sequelae has been evaluated. Proof of clinical advantage was most prominent for audiologic results.
Numerous clinical trials focused on the impacts of corticosteroids on audiologic
outcomes in patients with Hib meningitis. In a double-blind, placebo-controlled
research, patients were given cefuroxime or ceftriaxone in addition to either dexamethasone or placebo, 13 of 84 placebo group patients (15%), and 3 of 92 patients
in the dexamethasone group (3.3%) had moderate or more severe bilateral HL.The
efcacy of dexamethasone on SNHL was documented only for patients having Hib
meningitis. In this study, there were too few patients with meningitis by other organisms to assess whether dexamethasone has the same effect in these cases [26]. One
prospective, multicenter, placebo-controlled clinical trial with 143 children with
bacterial meningitis demonstrated no signicant overall difference between patients
given dexamethasone and those given a placebo for SNHL. The only subgroup
where a benet was observed with dexamethasone was that of patients with Hib
meningitis [27]. In the following years, several reviews of the studies advocated the
benet of supplementary dexamethasone in hearing outcomes of infants and children suspected or proven to have Hib meningitis [28–30].
In 2010, a meta-analysis of 24 studies involving 4041 participants showed that
corticosteroids obviated severe HL and any HL in children with bacterial meningitis. Analysis of subgroups for causative organisms indicated that corticosteroids
minimized severe HL in Hib meningitis [31]. A recent meta-analysis of 25 studies
involving 4121 participants (2511 pediatric patients, most children had meningitis
due to Hib) showed that corticosteroids minimized severe HL in children with Hib
meningitis but not in children with meningitis of non-Haemophilus species. Further
analysis of the country’s income level where the individual studies were conducted
indicated that dexamethasone decreased the severe HL rate among children in highincome countries but not in low and middle-income countries [11].
In experimentally induced Hib meningitis, a single ceftriaxone dose given intravenously resulted in a signicant increase in LOS and tumor necrosis factor-alpha
(TNF-α) concentrations in CSF 2 h later, as compared with the levels in untreated
animals. Dexamethasone signicantly reduced TNF-α concentrations and indexes
of meningeal inammation in CSF when administered with antibiotic simultaneously, but not if it was given 1h later [32]. Similarly, concentrations of free endotoxin and TNF-α in CSF increased 2–6 h after the rst dose of ceftriaxone in infants
with Hib meningitis [33]. In another placebo-controlled, double-blind trial of dexamethasone treatment in Hib meningitis, including 101 infants and children, patients
received either dexamethasone or a placebo with cefotaxime. When dexamethasone
was administered before the initiation of cefotaxime treatment (15–20min before),
the indexes of meningeal inammation and concentrations of cytokines in CSF
improved rapidly and signicantly compared with the patients given only

30 Haemophilus inuenzae Type b Meningitis inChildren andHearing Loss
https://t.me/medicina_free
465
cefotaxime [34]. It is generally recommended that adjunctive dexamethasone be
benecial if given just before or concurrently with the rst antimicrobial agent(s)
dose in Hib meningitis [28]. It can be explained by the rapid killing of bacteria in
the CSF, which releases toxic cell products and can lead to additional neurologic
injury [35].
In the early stages of bacterial meningitis, SNHL typically develops and progresses within 48h [36–38]. Histopathologic studies in animals with Hib meningitis
indicate that labyrinthitis is a probable cause of SNHL [36, 39]. The pathophysiology of labyrinthitis associated with bacterial meningitis was investigated by histopathologically examining the inner ears of 114 rats with Hib meningitis [36]. Except
for the endolymphatic space, cochlear nerve bers, and middle ear, the perilymphatic spaces of the cochlea and semicircular canals were inamed. The inammation reached a peak 48h after inoculation. Immunouorescent staining of cochleae
demonstrated the presence of bacteria in the inamed areas and the endolymphatic
space and organ of Corti. In a histopathology study of 41 human temporal bones
after death from acute bacterial meningitis, 20 (41%) temporal bones had suppurative labyrinthitis, and the cochlea was affected [40]. While the cochlear aqueduct
was the sole pathway for spreading infection in the rabbit, in humans, the modiolus
and the aqueduct were potential pathways suggested. It is mainly accepted that the
transmission of infection from the subarachnoid space to the labyrinth is the cause
of HL, and both the cochlear aqueduct and the cochlear nerve in the modiolus are
the potential pathways of the infection extension [41]. Inammatory cell inltration, serobrinous exudate formation, and granulation cells also indicate cochlear
pathology [41–43]. Vascular events such as septic emboli and thrombotic occlusion
of the cochlear artery and vein result in cochlear hypoxia, ischemia, and neural
damage [44]. Inammatory products such as nitric oxide and superoxide induce
cytotoxic injury on the cochlea by destroying the blood–labyrinth barrier [9].
Diagnostic techniques of SNHL are complementary and vary according to the
patient’s developmental age (cooperative or uncooperative). As soon as SNHL is
identied through the screening, age-appropriate testing will be implemented. If a
child cannot complete behavioral audiometric tests, otoacoustic emission (OAE)
and brainstem auditory evoked response (BAER) testing should be performed,
which requires more time and expertise to interpret but elicits more detailed information [45]. Otoacoustic emission tests are rapid and easy to perform. According to
the European Society of Clinical Microbiology and Infectious Diseases (ESCMID)
guidelines, OAE is used for screening children with bacterial meningitis [12]. In
case of failure, children are referred for a further hearing evaluation, such as BAER
testing or speech tone audiometry, according to the patient’s age [12].
Imaging the temporal bone and cochlea are needed for profound SNHL after
meningitis before cochlear implantation [46]. Computed tomography (CT) or magnetic resonance (MR) imaging may be done depending on the decision of the otolaryngologist. Magnetic resonance imaging can visualize the detailed inner ear
anatomy and allows for rapid cochlear implantation if a risk of cochlear obliteration
presents itself [47]. Gadolinium-enhanced MR imaging effectively predicted SNHL
by detecting labyrinthitis in the early phase of bacterial meningitis in children [48].

466
https://t.me/medicina_free
Sensorineural HL rehabilitation is vital for normal speech and language and the
child’s educational and social development. Cochlear implantation is a treatment
option in patients with bilateral SNHL after bacterial meningitis [47]. A cochlear
implant is a neuroprosthetic device surgically implanted to stimulate the auditory
nerve. Cochlear implantation is approved by the USA Food and Drug Administration
(FDA) for children aged 12–24months with profound bilateral SNHL and those
older than 24months with bilateral severe to profound SNHL.No FDA approval
exists for implantation in children below 12months of age. Implantation candidates
are also determined through comprehensive audiologic and developmental evaluation [49]. Since any delay decreases the success rates of cochlear implantation
because of cochlear brosis and calcication, early determination of SNHL secondary to meningitis is crucial [44].
There is a consensus that SNHL should be detected early, and if detected, it
should be monitored regularly. Various suggestions exist for the long-term audiologic follow-up of patients with no SNHL at the initial assessment [50–53]. Some
countries do not recommend further testing in case of a normal initial hearing test
after meningitis [50]. Conversely, several hearing evaluations are recommended
after bacterial meningitis in other countries [51]. The ESCMID guideline recommends follow-up testing in patients with no SNHL during the initial hospitalization
[12]. Spontaneous SNHL regressions, uctuations, or progressions may also be
observed after recovery from meningitis [41, 42]. A study reported that 8% (5 of 64)
and 10% (7 of 71) of children with Hib meningitis had profound SNHL in short- and
long-term follow-ups [16]. Another study described progressive HL over 11years
following Hib meningitis [52]. Close monitoring seems helpful for SNHL in patients
with Hib meningitis.
T. A. Teke et al.
30.10 Postexposure Chemoprophylaxis
Postexposure prophylaxis is important for preventing secondary cases. High-risk
groups for secondary infection are unimmunized or incompletely immunized children exposed to invasive Hib disease in childcare or household settings [8]. Children
below the age of 4years are at higher risk for Hib disease following household
contact [2]. Chemoprophylaxis can eliminate nasopharyngeal colonization and
reduce invasive Hib disease risk in susceptible people [1].
Rifampin has been reported to eradicate Hib from the nasopharynx in nearly
95% of carriers. Studies have also demonstrated its effectiveness in preventing secondary invasive Hib cases [6]. A dose of rifampin at 20mg/kg once daily orally
(600mg maximum) for 4 days, administered for Hib prophylaxis, should be initiated as soon as possible [6]. Prophylaxis with rifampin is to be used for all household contacts in the following conditions: in households having at least one infant
below 12months with incomplete primary Hib vaccine series, in households with at
least one child below 4 years that are not fully vaccinated, and in families with an
immunocompromised child regardless of their Hib immunization status or age. In
addition, prophylaxis is recommended for all contacts if two or more invasive Hib

30 Haemophilus inuenzae Type b Meningitis inChildren andHearing Loss
https://t.me/medicina_free
disease cases happen within 60days in attendees of a childcare facility and incompletely vaccinated children attend the facility. If the index patient is below 2 years
old or a household member with susceptible contact and was treated with a regimen
other than cefotaxime or ceftriaxone, prophylaxis will be given at the end of the
treatment. As per the immunization schedule, unimmunized or incompletely immunized children are supposed to receive the Hib vaccine.
467
30.11 Prevention
Routine use of Hib vaccines in infants and children is the most effective prevention
method for meningitis. The Hib conjugate vaccine is produced with the conjugation
of the Hib capsular polysaccharide PRP to carrier proteins. Conjugate vaccines are
highly effective for invasive Hib infections in infants and children. Besides their
preventive effects, these vaccines prevent nasopharyngeal colonization with Hib
and provide herd immunity [4]. The Hib conjugate vaccine doses are administered
at 8 weeks intervals (a minimum of 4weeks) [8]. The primary series of Hib vaccines
have either three doses, administered at 2, 4, and 6months of age, or two doses at 2
and 4months, depending on the vaccine products. The rst dose may also be administered at 6 weeks of age. A booster dose is administered between 12 and 15months
of age. High-risk groups for invasive Hib disease include children with sickle cell
disease, functional or anatomic asplenia, human immunodeciency virus (HIV)
infection, certain immunodeciency syndromes, bone marrow transplants, and
patients receiving chemotherapy [6].
30.12 Conclusion
In children, bacterial meningitis is the leading cause of acquired SNHL [44]. The
administration of conjugate vaccines has led to a dramatic decrease in the incidence
of Hib meningitis. Despite effective antimicrobial treatment and timely administration of dexamethasone, SNHL may occur in patients with Hib meningitis, so the
increased effort for vaccination is essential in preventing the disease. Sensorineural
HL has several long-term complications, including speech and language difculties
and intellectual and behavioral disabilities. So, the early determination of HL is
critical. Sensorineural HL caused by meningitis can be subtle, especially in infants.
Routine follow-up after bacterial meningitis should include a hearing evaluation.
There should be a prompt referral of children recovering from bacterial meningitis
for audiologic assessment. When SNHL is detected, the child is evaluated for
cochlear implantation, the current surgical management of children with SNHL.If
there is no HL in initial hearing tests, it is unclear whether follow-up testing is
needed. Because uctuations or progressions of SNHL are reported after bacterial
meningitis, close follow-up is required.

468
https://t.me/medicina_free
T. A. Teke et al.
References
1. Kadry NA, Geme JW 3rd. Haemophilus inuenzae. In: Long SS, Prober CG, Fischer
M, Kimberlin D, editors. Principles and practice of pediatric infectious diseases. 6th ed.
Philadelphia: Elsevier; 2023. p.945–51.
2. Barenkamp SJ. Haemophilus inuenzae. In: Cherry J, Harrison GJ, Kaplan SL, Steinbach
WJ, Hotez PJ, editors. Feigin and Cherry’s textbook of pediatric infectious diseases. 8th ed.
Philadelphia: Elsevier; 2019. p.1199–211.
3. Oliver SE, Moro P, Blain AE.Haemophilus inuenzae. In: Hall E, Wodi AP, Hamborsky J,
Morelli V, Schillie S, editors. Centers for Disease Control and Prevention Pink Book 2021:
epidemiology and vaccine-preventable diseases. 14th ed. Washington, DC: Public Health
Foundation; 2021. p. 111–24. https://www.cdc.gov/vaccines/pubs/pinkbook/downloads/hib.
pdf. Accessed 25 Nov 2022.
4. Murphy TF. Haemophilus species, including H. inuenzae and H. ducreyi (chancroid). In:
Bennett JE, Dolin R, Blaser MJ, editors. Mandell, Douglas, and Bennett’s principles and practice of infectious diseases. 9th ed. Philadelphia: Elsevier; 2020. p.2743–52.
5. van de Beek D, Brouwer MC, Koedel U, Wall EC.Community-acquired bacterial meningitis.
Lancet. 2021;398:1171–83.
6. American Academy of Pediatrics. Haemophilus inuenzae infections. In: Kimberlin DW,
Barnett ED, Lyneld R, Sawyer MH, editors. Red Book: 2021–2024 report of the committee
on infectious diseases. 32nd ed. Itasca, IL: American Academy of Pediatrics; 2021. p.345–54.
7. Abou-Hanna J, Panning K, Mehta H. Haemophilus inuenza type f meningitis complicated
by bilateral subdural empyema, central venous thrombosis, and bilateral sensorineural hearing
loss in an immunocompetent 12-month-old. Cureus. 2019;11:e4850.
8. Butler DF, Myers AL.Changing epidemiology of Haemophilus inuenzae in children. Infect
Dis Clin N Am. 2018;32:119–28.
9. Tan YC, Gill AK, Kim KS. Treatment strategies for central nervous system infections: an
update. Expert Opin Pharmacother. 2015;16:187–203.
10. American Academy of Pediatrics. Systemic and topical antimicrobial dosing and dose forms.
In: Bradley JS, Nelson JD, Barnett ED, etal., editors. 2022 Nelson’s pediatric antimicrobial
therapy. 28th ed. Itasca, IL: American Academy of Pediatrics; 2022. p.273–306.
11. Brouwer MC, McIntyre P, Prasad K, van de Beek D.Corticosteroids for acute bacterial meningitis. Cochrane Database Syst Rev. 2015;2015(9):CD004405.
12. van de Beek D, Cabellos C, Dzupova O, etal. ESCMID guideline: diagnosis and treatment of
acute bacterial meningitis. Clin Microbiol Infect. 2016;22:37–62.
13. Fortnum H, Davis A.Hearing impairment in children after bacterial meningitis: incidence and
resource implications. Br J Audiol. 1993;27:43–52.
14. Taylor HG, Schatschneider C, Watters G. Acute-phase neurologic complications of
Haemophilus inuenzae type b meningitis: association with developmental problems at school
age. J Child Neurol. 1998;13:113–9.
15. Pomeroy SL, Holmes SJ, Dodge PR, etal. Seizures and other neurological sequela of bacterial
meningitis in children. N Engl J Med. 1990;323:1651–7.
16. Ahmed ASMNU, Khan NZ, Hussain M, etal. Follow-up of cases of Haemophilus inuenza
type b meningitis to determine its long-term sequelae. J Pediatr. 2013;163:44–9.
17. Zainel A, Mitchell H, Sadarangani M.Bacterial meningitis in children: neurological complications, associated risk factors, and prevention. Microorganisms. 2021;9:535.
18. Ramakrishnan M, Ulland AJ, Steinhardt LC, Moïsi JC, Were F, Levine OS. Sequelae due
to bacterial meningitis among African children: a systematic literature review. BMC Med.
2009;7:47.
19. Jatto ME, Adeyemo AA, Ogunkeyede SA, Lagunju IA, Nwaorgu OG. Pediatric hearing
thresholds post-bacterial meningitis. Front Surg. 2020;7:36.

30 Haemophilus inuenzae Type b Meningitis inChildren andHearing Loss
https://t.me/medicina_free
20. Orman G, Kukreja MK, Vallejo JG, Desai N, Huisman TAGM, KralikSF.Accuracy of MR
imaging for detection of sensorineural hearing loss in infants with bacterial meningitis. Am J
Neuroradiol. 2020;41:1081–6.
21. Feldman WE, Ginsburg CM, Mc Cracken GH, etal. Relations of concentrations of Haemophilus
inuenzae type b in cerebrospinal uid to late sequela of patients with meningitis. J Pediatr.
1982;100:209–12.
22. Mertsola J, Kennedy WA, Waagner D, etal. Endotoxin concentrations in cerebrospinal uid
correlate with clinical severity and neurologic outcome of Haemophilus inuenzae type b meningitis. Am J Dis Child. 1991;145:1099–103.
23. Tunkel AR, Wispelwey B, Scheld WM.Bacterial meningitis: recent advances in pathophysiology and treatment. Ann Intern Med. 1990;112:610–23.
24. Tunkel AR, Scheld WM. Pathogenesis and pathophysiology of bacterial meningitis. Clin
Microbiol Rev. 1993;6:118–36.
25. Tunkel AR. Practice guidelines for the management of bacterial meningitis. Clin Infect Dis.
2004;39:1267–84.
26. Lebel MH, Freij BJ, Syrogiannopoulos GA, etal. Dexamethasone therapy for bacterial meningitis: results of two double-blind, placebo-controlled trials. N Engl J Med. 1988;319:964–71.
27. Wald ER, Kaplan SL, Mason EO, etal. Dexamethasone therapy for children with bacterial
meningitis. Meningitis Study Group. Pediatrics. 1995;95:21–8.
28. Tunkel AR, Scheld WM.Acute bacterial meningitis. Lancet. 1995;346:1675–80.
29. Quagliarello VJ, Scheld WM. Treatment of bacterial meningitis. N Engl J Med.
1997;336:708–16.
30. Wubbel L, McCracken GH. Management of bacterial meningitis: 1998. Pediatr Rev.
1998;19:78–84.
31. Brouwer MC, McIntyre P, Prasad K, van de Beek D.Corticosteroids for acute bacterial meningitis. Cochrane Database Syst Rev. 2010;2010(9):CD004405.
32. Mustafa MM, Ramilo O, Mertsola J, etal. Modulation of inammation and cachectin activity
in relation to treatment of experimental Hemophilus inuenzae type b meningitis. J Infect Dis.
1989;160:818–25.
33. Arditi M, Ables L, Yogev R.Cerebrospinal uid endotoxin levels in children with H. inu-
enzae meningitis before and after administration of intravenous ceftriaxone. J Infect Dis.
1989;160:1005–11.
34. Odio CM, Faingezicht I, Paris M, etal. The benecial effects of early dexamethasone administration in infants and children with bacterial meningitis. N Engl J Med. 1991;324:1525–31.
35. Esposito S, Semino M, Picciolli I, Principi N.Should corticosteroids be used in bacterial meningitis in children? Eur J Pediatr Neurol. 2013;17:24–8.
36. Wiedermann BL, Hawkins EP, Johnson GS, Lamberth LB, Mason EO, Kaplan SL.Pathogenesis
of labyrinthitis associated with Haemophilus inuenzae type b meningitis in infants rats. J
Infect Dis. 1986;153:27–32.
37. Kaplan SL, Catlin FI, Weaver T, Feigin RD.Onset of hearing loss in children with bacterial
meningitis. Pediatrics. 1984;73:575–8.
38. Vienny H, Despland PA, Liitschg J, Deonna T, Dutoit-Marco ML, Gander C.Early diagnosis
and evolution of deafness in childhood bacterial meningitis: a study using brainstem auditory
evoked potentials. Pediatrics. 1984;73:579–86.
39. Moxon ER, Smith AL, Averill DR, Smith DH. Haemophilus inuenzae meningitis in infant
rats after intranasal inoculation. J Infect Dis. 1974;129:154–62.
40. Merchant SN, Gopen Q.A human temporal bone study of acute bacterial meningogenic labyrinthitis. Am J Otol. 1996;17:375–85.
41. Du Y, WuX LL.Mechanisms of bacterial meningitis-related deafness. Drug Discov Today.
2006;3:115–8.
42. Kenna MA.Acquired hearing loss in children. Otolaryngol Clin N Am. 2015;48:933–53.
43. Beijen J, Casselman J, Joosten F, etal. Magnetic resonance imaging in patients with meningitisinduced hearing loss. Eur Arch Otorhinolaryngol. 2009;266:1229–36.
469

470
https://t.me/medicina_free
44. Wellman MB, Sommer DD, McKenna J.Sensorineural hearing loss in postmeningitic children. Otol Neurotol. 2003;24:907–12.
45. Hart CK, Choo DI.What is the optimal workup for a child with bilateral sensorineural hearing
loss? Laryngoscope. 2013;123:809–10.
46. Roukema BY, Van Loon MC, Smits C, etal. Cochlear implantation after bacterial meningitis
in infants younger than 9 months. Int J Otolaryngol. 2011;2011:845–79.
47. van Loon MC, Hensen EF, de Foer B, Smit CF, Witte B, Merkus P.Magnetic resonance imaging in the evaluation of patients with sensorineural hearing loss caused by meningitis: implications for cochlear implantation. Otol Neurotol. 2013;34:845–54.
48. Kopelovich JC, Germiller JA, Laury AM, Shah SS, Pollock AN.Early prediction of postmeningitic hearing loss in children using magnetic resonance imaging. Arch Otolaryngol Head
Neck Surg. 2011;137:441–7.
49. Liu CC, Anne S, Horn DL.Advances in management of pediatric sensorineural hearing loss.
Otolaryngol Clin N Am. 2019;52:847–61.
50. Public Health England. Guidelines for surveillance and audiological referral of infants and
children following newborn hearing screen. London: Public Health England; 2012. Updated
19 Jul 2019. https://www.gov.uk/government/publications/surveillance- and- audiological-
referral- guidelines. Accessed 25 Nov 2022.
51. Merkus P, Free RH, Mylanus EA, et al. Dutch Cochlear Implant Group (CI-ON) consensus
protocol on postmeningitis hearing evaluation and treatment. Otol Neurotol. 2010;31:1281–6.
52. Silkes ED, Chabot J.Progressive hearing loss following Haemophilus inuenzae meningitis.
Int J Pediatr Otorhinolaryngol. 1985;9:249–56.
53. Rodenburg-Vlot MB, Ruytjens L, Oostenbrink R, Goedegebure A, van der Schroeff
MP.Systematic review: incidence and course of hearing loss caused by bacterial meningitis: in
search of an optimal timed audiological follow-up. Otol Neurotol. 2016;37:1–8.
T. A. Teke et al.

Gram-Negative Bacterial Meningitis
https://t.me/medicina_free
inChildren andHearing Loss
EdanurYeşil, MustafaHacımustafaoğlu, EminSamiArısoy,
andArmandoG.Correa
31.1 Introduction
The leading gram-negative bacteria causing acute bacterial meningitis (ABM) are
Neisseria meningitidis (meningococcus), Haemophilus inuenzae type b (Hib),
Salmonella spp., Acinetobacter spp., Pseudomonas spp., and enteric gram-negative
bacilli, including mainly Escherichia coli, and Klebsiella spp. This chapter primarily focuses on ABM caused by gram-negative bacteria, with neurological complications, especially hearing loss (HL), and its evaluation. In addition, the general
characteristics of ABM will also be briey discussed to highlight the distinctive
features of ABM caused by different pathogens.
E. Yeşil (*)
Division of Pediatric Infectious Diseases, Department of Pediatrics, Faculty of Medicine,
Mersin University, Mersin, Türkiye
e-mail: edanuryesil@mersin.edu.tr
M. Hacımustafaoğlu
Division of Pediatric Infectious Diseases, Department of Pediatrics, Faculty of Medicine,
Uludağ University, Bursa, Türkiye
e-mail: mkemal@uludag.edu.tr
E. S. Arısoy
Division of Pediatric Infectious Diseases, Department of Pediatrics, Faculty of Medicine,
Kocaeli University, Kocaeli, Türkiye
e-mail: emin.sami.arisoy@gmail.com
A. G. Correa
Division of Academic General Pediatrics, Department of Pediatrics, Baylor College of
Medicine, Houston, TX, USA
Section of International and Destination Medicine, Texas Children’s Hospital,
Houston, TX, USA
e-mail: acorrea@bcm.edu
31
© The Author(s), under exclusive license to Springer Nature
Switzerland AG 2023
A. E. Arısoy et al. (eds.), Hearing Loss in Congenital, Neonatal and Childhood
Infections, Comprehensive ENT, https://doi.org/10.1007/978-3-031-38495-0_31
471

472
https://t.me/medicina_free
E. Yeşil et al.
31.2 Etiology
Gram-negative bacteria, mainly N. meningitidis, Hib, and E. coli, are the signicant
agents of ABM.Gram-negative bacilli are among the common causes of ABM,
especially in newborns and infants younger than 3 months [1]. Gram-negative
bacilli are a common cause of healthcare-associated meningitis but rare as
community- acquired meningitis causes in older children and adults [2]. Gramnegative bacteria may cause infection in immunocompromised children and children with a ventriculoperitoneal shunt (VPS).
Pseudomonas species meningitis may occur following chronic cranial osteomyelitis, a rare complication of mastoiditis or trauma, and may also be seen in children
with immunodeciencies. Citrobacter diversus is a rare cause of meningitis in newborn infants but is associated with signicant morbidity and mortality. One-third of
newborns with Citrobacter meningitis die, and most survivors have signicant neu-
rological sequelae. Brain abscess is a common complication in neonatal C. diversus
meningitis [3]. Citrobacter freundii and C. diversus are rare causes of meningitis in
children and adults [2].
31.3 Epidemiology
In a surveillance study conducted in the United States of America (USA) between
2006 and 2007, the annual incidence of ABM was 81/100,000in children <2months,
7/100,000 between 2 months and 2 years, 0.6/100,000 in 2–10 years, and
0.4/100,000in 11–17years [4]. After the immunization programs for Hib and pneumococci with conjugate vaccines, the incidence of ABM decreased in all age groups.
However, the incidence remains high in infants under 2months of age, where the
effects of vaccines have not yet been seen [2].
Infants less than 3months (≤90days) are more vulnerable to infections than the
other age groups. Causative pathogens of meningitis may vary according to
age [5–8]:
• Newborn (0–28days): Group B streptococcus (GBS), E. coli, and other gram-
negative bacilli are the primary causative pathogens in neonatal ABM.
• Infants <3months (29–90days): Group B streptococcus, E. coli, other enteric
gram-negative bacilli, Streptococcus pneumoniae (pneumococcus), N. menin-
gitidis, more rarely Enterococcus spp., Staphylococcus aureus, Listeria monocy-
togenes, group A streptococcus (GAS), and Hib may be seen [3, 5].
• Infants >3 months (≥90 days) and children: Streptococcus pneumoniae and
N. meningitidis are common pathogens. Group A streptococcus, GBS, Hib, and
other gram-negative microorganisms are less commonly seen.
• In adolescents: Neisseria meningitidis is the most common pathogen [3, 5].
Escherichia coli, Klebsiella spp., and Pseudomonas spp. cause %14 cases of
gram-negative ABM in infants worldwide [9].

31 Gram-Negative Bacterial Meningitis inChildren andHearing Loss
https://t.me/medicina_free
According to geographical regions, pneumococci in North America and meningococci in Europe and sub-Saharan Africa are the most common causes of ABM [3,
5]. Meningococcal serogroup B and A meningitis are more common in Europe and
Africa, respectively [3, 5]. However, meningococcal serogroup distribution may
change over the years, even in the same geographical area. So, the actual
epidemiology- based variations of different countries or regions should be checked
for pretravel vaccination [3, 5].
Gram-negative bacillary meningitis primarily occurs in specic situations,
including neonatal, post-traumatic, healthcare-associated, post-brain surgery, and
spontaneous gram-negative meningitis in adults and VPS infections [3, 5]. Most
neonates with meningitis are infected with E. coli strains containing K1 capsular
polysaccharides, which can help the organism to be saved from host defense [3, 5].
In newborns and infants, gram-negative bacillary meningitis may be associated with
neural tube defects and urinary tract anomalies. Any condition that disrupts the dura
mater integrity, such as neurosurgery or trauma, may predispose to meningeal infection and cause gram-negative bacterial meningitis. This probability is relatively
increased when antimicrobial prophylaxis is given predominantly for gram-positive
coverage to prevent surgical site infection [2, 5].
473
31.4 Pathogenesis andPathophysiology
The most common mechanism in the invasion of the causative agent to the central
nervous system (CNS) is the nasopharyngeal colonization of the pathogen, such as
Hib, meningococcus, and pneumococcus, usually acquired by droplets rst, then
passing through the blood circulation and penetrating the subarachnoid space from
the capillary endothelium.
The second way is the direct entry of the microorganism to the CNS by contiguous infections, such as complicated sinusitis, mastoiditis, septic cerebral venous
thrombus, or by direct spread from a congenital neural tube defect or cerebrospinal
uid (CSF)-related pilonidal sinus, trauma, neurosurgery, CSF leakage, or through
medical devices such as VPSs, and cochlear implants. This pathogenetic mechanism
is more likely for gram-negative bacillary meningitis. However, in cases of dural tear
and/or CSF leakage secondary to head trauma, pathogens that tend to colonize the
mucosa and skin, such as pneumococci and staphylococci, may also be seen.
Thirdly, meningitis may develop with the invasion of the CNS following bacteremia from a different localized source, such as a catheter infection, infective endocarditis, or complicated urinary tract infection [5]. This mechanism is more common
in patients with immunodeciencies, such as meningococcal meningitis in terminal
complement deciencies.
Most signicant meningitis pathogens have surface components such as mbriae
or pili that increase mucosal colonization. Meningococci use a variety of receptors,
including the platelet-activating factor receptor, beta-2 adrenergic receptors, and
CD147, for adhesion through type IV pili. Outer membrane proteins (OpC and
OpA) also contribute to establishing and maintaining adhesion [10, 11]. Also,
Соседние файлы в папке Библиотека им академика М.И. Перельмана
